• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Digital Biomarkers

Detect Depression in Seconds Wellin5 x Kintsugi Voice Biomarker Integration

by Syed Hamza Sohail 02/20/2024 Leave a Comment

Detect Depression in Seconds Wellin5 x Kintsugi Voice Biomarker Integration

What You Should Know: Wellin5, the premier provider of online counseling, proudly announces a new partnership with Kintsugi, an AI mental health technology leader.This collaboration comes at a time when Wellin5 has successfully navigated the turbulent economic landscape and challenges in the health tech space to thrive and bring this vital partnership to life, setting a new standard in mental health care for over 50,000 clients based in Canada and the USA. Revolutionizing
Read More

Empatica Awarded New FDA Clearance for Cardiac Digital Biomarkers

by Fred Pennic 11/06/2023 Leave a Comment

Empatica Awarded New FDA Clearance for Cardiac Digital Biomarkers

What You Should Know: - Empatica, a digital health and AI company, has obtained FDA 510(k) clearance for two new digital biomarkers, pulse rate, and respiratory rate, on its Empatica Health Monitoring Platform. - This clearance expands the platform to include a total of six FDA-cleared digital biomarkers, out of the 128 digital measures supported, making it one of the most comprehensive solutions available for use in clinical trials. - The Empatica Health Monitoring Platform comprises a
Read More

23andMe Launches Health Action Plan Based on Genetic/Health Data

by Fred Pennic 10/31/2023 Leave a Comment

23andMe Launches Health Action Plan Based on Genetic/Health Data

What You Should Know:  - 23andMe, a genetic health and biopharmaceutical company launched Health Action Plan, a new digital tool for 23andMe+ members that draws on results from genetic reports, health history survey data, as well as blood and biomarker data to provide a uniquely tailored set of health recommendations out of hundreds of options. - Health Action Plan is a helpful first step when it comes to prevention and early risk detection. It offers customers specific actions and
Read More

The Future of Biomarker-Based Therapy for Mental Disorder Care

by Oded Kraft, Co-Founder & CEO of GrayMatters Health. 10/26/2023 Leave a Comment

The Future of Biomarker-Based Therapy for Mental Disorder Care

We are living in a mental health epidemic. An estimated 26 percent of Americans ages 18 and older – about one in four adults – suffer from a diagnosable mental disorder in a given year. Among mental disorders, cases of PTSD are on the rise. Roughly five percent of American adults suffer from PTSD in any given year and more than 13 million Americans reported PTSD in 2020 – most of whom are women. Standard PTSD treatments most often come in the form of pharmacotherapy or psychotherapy and include
Read More

Mount Sinai Researchers Identify Biomarker That Tracks Recovery From Treatment-Resistant Depression

by Syed Hamza Sohail 09/20/2023 Leave a Comment

Mount Sinai Researchers Identify Biomarker That Tracks Recovery From Treatment-Resistant Depression

What You Should Know: A team of leading clinicians, engineers, and neuroscientists has made a groundbreaking discovery in the field of treatment-resistant depression. By analyzing the brain activity of patients undergoing deep brain stimulation (DBS), a promising therapy involving implanted electrodes that stimulate the brain, the researchers identified a unique pattern in brain activity that reflects the recovery process in patients with treatment-resistant depression.This pattern, known as
Read More

ALZpath Secures Funding for Blood-Based Biomarker Testing for Alzheimer’s Disease Detection

by Fred Pennic 07/21/2023 Leave a Comment

ALZpath Secures Funding for Blood-Based Biomarker Testing for Alzheimer's Disease Detection

What You Should Know:  - ALZpath, a developer of blood-based diagnostic biomarker testing for Alzheimer's disease detection receives funding from the Alzheimer’s Drug Discovery Foundation (ADDF)’s Diagnostics Accelerator to accelerate the clinical availability  of ALZpathDx as a laboratory developed test (LDT).  - ALZpathDx is a novel, proprietary assay for blood-based measurement of phosphorylated tau at threonine 217 (pTau217), a highly accurate, diagnostic biomarker for
Read More

Sonde Health Secures $19.25M for Voice-Based Health Monitoring

by Fred Pennic 12/08/2022 Leave a Comment

Sonde Health Secures $19.25M for AI Vocal Biomarker Platform

What You Should Know: - Sonde Health, a Boston, MA-based health technology company committed to bringing accessible health monitoring to everyone raises $19.25 million in a Series B investment round led by Partners Investment, with participation from NEOM Company, KT Corporation, and existing investors, including co-founder PureTech Health and M Ventures. - The AI vocal biomarker company will use the funding to accelerate its commercial growth, expand its platform into new health
Read More

How Biosensing Tech Can Alleviate Dehydration in Older Adults

by Jennifer Corso (Kukral), Upstream Marketing Manager, Physiology, Rockley Photonics 11/15/2022 Leave a Comment

How Biosensing Tech Can Alleviate Dehydration in Older Adults

For most adults, the first sign of dehydration is feeling thirsty. However, as we age, our thirst sensation naturally weakens, which means older people may not know that they need more fluids until they’re typically underhydrated, putting them at a higher risk of clinical dehydration. Other age-related physiological changes can also impact a person’s ability to remain hydrated, such as a decline in kidney function. Indeed, renal function begins to diminish around the age of 50. This is due
Read More

NeuroSense Therapeutics and NeuraLight Collaborate to Detect ALS Oculometric Biomarkers

by Syed Hamza Sohail 07/28/2022 Leave a Comment

NeuroSense Therapeutics and NeuraLight Collaborate to Detect ALS Oculometric Biomarkers

What You Should Know: - NeuroSense Therapeutics Ltd., a company developing treatments for severe neurodegenerative diseases, and NeuraLight, a company developing objective and sensitive biomarkers for neurological disorders, today announced a collaboration to advance the science of digital biomarkers in the detection and monitoring of neurological diseases including amyotrophic lateral sclerosis (ALS). - This agreement marks NeuraLight’s first clinical trial and comes on the heels of
Read More

Imagene Raises $21.5M to Expand Image-Based Biomarker Detection for Precision Medicine

by Fred Pennic 05/02/2022 Leave a Comment

Imagene Raises $21.5M to Expand Image-Based Biomarker Detection for Precision Medicine

What You Should Know: - Imagene AI, an emerging leader in the field of AI-based precision medicine for cancer, today announced it raised $21.5 million, comprising $3M in seed funding led by Blumberg Capital and an $18.5M Series A round led by renowned technology-driven cancer medicine investors Larry Ellison, Dr. David Agus, and AI imaging space pioneer Eyal Gura. - The use of AI-based molecular testing in cancer diagnostics is revolutionizing patient care by offering a new level of
Read More

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Next Page

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |